Skip to main content

Table 3 Tumor parameters for patients with a clear-cell tumor, also stratified by VHL mutation status

From: Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study

 

All tumors (N = 188)

VHL mutated tumors (N = 115)

Wildtype tumors (N = 73)

  
 

N

%

N

%

N

%

χ2

p-value †

T (TNM*)

        

1

5

2.7

4

3.5

1

1.4

  

2

93

49.5

55

47.8

38

52.1

  

3A

35

18.6

20

17.4

15

20.6

  

3B

50

26.6

34

29.6

16

21.9

  

4

2

1.1

1

0.9

1

1.4

0.18§**

0.67

X

3

1.6

1

0.9

2

2.7

  

N (TNM*)

        

0

126

67.0

78

67.8

48

65.8

  

1

7

3.7

6

5.2

1

1.4

  

2

7

3.7

5

4.4

2

2.7

1.51¶**

0.22

X

48

25.5

26

22.6

22

30.1

  

M (TNM*)

        

0

131

69.7

77

67.0

54

74.0

  

1

26

13.8

18

15.7

8

11.0

0.99**

0.32

X

31

16.5

20

17.4

11

15.1

  

Stage (TNM*)

        

1

5

2.7

4

3.5

1

1.4

  

2

83

44.2

46

40.0

37

50.7

  

3

66

35.1

42

36.5

24

32.9

  

4

32

17.0

22

19.1

10

13.7

1.41§**

0.24

X

2

1.1

1

0.9

1

1.4

  

Nuclear grading †‡

        

I

46

24.5

27

23.5

19

26.0

  

II

67

35.6

43

37.4

24

32.9

  

III

48

25.5

29

25.2

19

26.0

  

IV

27

14.4

16

13.9

11

15.1

0.43

0.94

  1. * Based on pathological TNM unless unknown, then clinical TNM (UICC, 1987) was used [17]
  2. † Based on the review by one experienced pathologist (CAHK)
  3. ‡ According to Fuhrman [19]
  4. §1–2 vs. 3–4
  5. ¶1–2 vs. 0
  6. ** Excludes "X (unknown) " category